印度第一种与生物相似的癌症药物TishthaTM, Zydus Lifesciences launches India’s first biosimilar cancer drug, Tishtha™, at a fraction of the cost to improve treatment access.

齐达斯生命科学公司推出了印度第一种生物仿制药TishthaTM, Zydus Lifesciences has launched Tishtha™, India’s first biosimilar of the cancer drug nivolumab, for treating cancers like melanoma, lung cancer, and kidney cancer. 100毫克为28,950分,40毫克为13,950分,价格约为原药的四分之一,目的是改善获取机会,减少废物。 Priced at ₹28,950 for 100 mg and ₹13,950 for 40 mg, it costs about one-fourth of the original drug, aiming to improve access and reduce waste. 发起活动支持开展更广泛的努力,使印度的肿瘤治疗更加负担得起,并与全球采用生物类同的趋势保持一致。 The launch supports broader efforts to make oncology treatments more affordable in India and aligns with global trends toward biosimilar adoption.